(Q37145404)

18 August 2017

1 reference

title

Safety of parathyroid hormone for the treatment of osteoporosis (English)

1 reference

18 August 2017

0 references

Paul D Miller

1

1 reference

18 August 2017

1 March 2008

1 reference

Current osteoporosis reports

18 August 2017

1 reference

18 August 2017

6

1 reference

18 August 2017

1

1 reference

18 August 2017

12-16

1 reference

https://scigraph.springernature.com/pub.10.1007/s11914-008-0003-y

18 August 2017

0 references

cites work

Long-term risk of sarcoma following radiation treatment for breast cancer.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11914-008-0003-Y

Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study

21 January 2018

1 reference

12 December 2020

Osteosarcoma and teriparatide?

1 reference

12 December 2020

1 reference

12 December 2020

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

1 reference

12 December 2020

Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate.

1 reference

12 December 2020

Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report

1 reference

12 December 2020

Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects

1 reference

12 December 2020

1 reference

12 December 2020

Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy

1 reference

12 December 2020

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

1 reference

12 December 2020

Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis

1 reference

12 December 2020

Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

Pathogenesis of secondary hyperparathyroidism

1 reference

12 December 2020

Parathyroid hormone and periosteal bone expansion

1 reference

12 December 2020

Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study

1 reference

12 December 2020

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

1 reference

12 December 2020

Urinary calcium in perimenopausal women: normative values

1 reference

12 December 2020

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

1 reference

12 December 2020

Reduced risk of back pain following teriparatide treatment: a meta-analysis

1 reference

12 December 2020

Mechanisms of anabolic therapies for osteoporosis

1 reference

12 December 2020

Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review

1 reference

12 December 2020

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

1 reference

12 December 2020

Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis

1 reference

12 December 2020

Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis

1 reference

12 December 2020

Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide

1 reference

12 December 2020

Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.

1 reference

12 December 2020

Clinical use of teriparatide in the real world: initial insights

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

The Vitamin D requirement in health and disease

1 reference

12 December 2020

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

1 reference

12 December 2020

1 reference

12 December 2020

Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose

1 reference

12 December 2020

Radiation-induced sarcomas of bone: factors that affect outcome

1 reference

12 December 2020

The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis

1 reference

12 December 2020

10.1007/S11914-008-0003-Y

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18430395